Society Picks of The Week

QSAM Biosciences Inc.
(OTCQB: QSAM)

QSAM Biosciences Inc. (OTCQB: QSAM) is a clinical stage biotechnology company focused on bringing to market targeted therapeutic radiopharmaceuticals. The company is committed to advancing the fight against cancer through the discovery, development and delivery of effective treatment options for adult and pediatric patients.

QSAM Biosciences was founded in 2020 by Executive Chairman Dr. C. Richard Piazza and CEO Douglas Baum. It is headquartered in Austin, Texas.

CycloSam®

CycloSam®, QSAM Biosciences’ initial technology, is a clinical-stage bone targeting radiopharmaceutical invented by world-renowned scientists at IsoTherapeutics Group LLC. By leveraging a patented, low specific activity form of Samarium-153 (resulting in far less undesirable europium impurity) and what management believes to be a superior chelating agent in DOTMP, CycloSam is designed to selectively target sites of high bone mineral turnover to deliver a prescribed tumor-killing dose of radiation to the bone tumor sites while minimizing radiation exposure to nearby healthy tissue. These parameters are currently being tested in an FDA-cleared clinical trial.

CycloSam® has been shown in laboratory testing to cause significantly less (30x less) buildup of long-lived radionuclidic impurities than prior FDA-approved drugs, which management believes will enable the ability to safely administer therapeutic doses via higher and multiple-dose regimens and effectively expand its potential clinical utility to therapeutic uses in areas of high unmet medical needs.

The indications for CycloSam® currently being evaluated by QSAM Biosciences include:

• Metastatic Bone Cancers – On April 28, 2022, QSAM Biosciences announced that the first patient had commenced treatment in its clinical trial evaluating CycloSam in patients with metastatic bone cancer. As noted in the release, the study is a Phase 1 open-label, dose-escalation trial to evaluate the safety, tolerability, dosimetry, and preliminary efficacy of CycloSam®.
• Pediatric Osteosarcoma/Ewing’s Sarcoma – On February 2, 2022, the company announced that the U.S. FDA has granted Rare Pediatric Disease Designation to CycloSam for the treatment of osteosarcoma. Combined with a previously granted orphan drug designation for osteosarcoma received in 2021, this milestone “may allow QSAM to potentially bring CycloSam® to market more rapidly through additional incentives and eligibilities,” according to CEO Douglas Baum.
• Bone Marrow Ablation – In a 2020 single patient Investigational New Drug (IND) study, an investigator concluded that high-dose CycloSam® can be administered safely to ablate bone marrow in advance of a stem cell transplant with no apparent renal toxicity and no unexpected adverse events attributable to the drug.

QSAM Biosciences’ preclinical and clinical development pipeline is supported by a strong IP portfolio. The company has secured 14 patents across three distinct patent families spanning the U.S., Japan, Canada and the European Union.

Investment Considerations

• QSAM Biosciences Inc. is committed to advancing the fight against cancer through the discovery, development and delivery of effective treatment options for adult and pediatric patients.
• CycloSam®, QSAM Biosciences’ initial technology, is a clinical-stage bone targeting radiopharmaceutical being evaluated for multiple indications.
• CycloSam has been shown to cause significantly less buildup of long-lived radionuclidic impurities than prior FDA-approved drugs.
• There is significant precedent that the radioisotope used in CycloSam, Samarium-153, is effective in treating bone cancer, as demonstrated in a published study conducted in over 500 patients using an older formulation of the drug.
• There is also significant preliminary safety precedent for Samarium-153, as shown through the 2020 single patient IND and the super-therapeutic dose administered in that study.
• QSAM Biosciences’ preclinical and clinical development pipeline is supported by a strong IP portfolio.
• The company is led be an experienced management team with an extensive record of FDA approvals, big pharma partnerships and M&A transactions.

- Recent Coverage -

August 1, 2022 10:00 AM
 

New research has identified a molecule that is involved in both cardiovascular disease and cancer metastasis. For cancer to become malignant, cells in tumors undergo various transformations that involve interactions between the tumor and an individual’s immune system.

While most of the details involved in this process are unclear, evidence has shown that endothelial cell inflammation plays a key role in a tumor’s progression to metastasis. Endothelial cells usually form a layer lining the blood vessels in the body, helping regulate exchanges between the bloodstream and surrounding tissue.

The study objective of the researchers at Hokkaido University was to look into the molecular mechanisms behind endothelial cell inflammation and how they were relevant to cancer malignancy. The research, which was led by Professor Kyoko Hida, discovered that endothelial cells accumulate low-density lipoprotein in malignant tumors and attract neutrophils, which are immune cells that contribute to the progression of tumors. Low-density lipoproteins are molecules which deliver lipids.

Freight Technologies Inc.
(NASDAQ: FRGT)

Freight Technologies Inc. (NASDAQ: FRGT) (“Fr8Tech”) is a technology company developing solutions to optimize and automate the supply chain process, providing a platform for B2B cross-border shipping in the NAFTA region. The company’s mission is to revolutionize cross-border shipping by providing carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road shipping.

Freight Technologies, formerly known as Hudson Capital Inc., assumed its current name and ticker symbol on May 27, 2022. Its primary operating subsidiary and its marketplace are known as Fr8App, and it conducts operations throughout North America under the names of Fr8App and/or Freight App. The company is headquartered in Houston, Texas, with multiple locations across the U.S. and Mexico.

The Fr8Tech Solutions Suite

Fr8Tech leverages artificial intelligence to provide cloud-based platforms aimed at automating the over-the-road transportation process, effectively reducing human touch points and expediting load booking times. The company’s suite of solutions includes:

• Fr8app – A B2B marketplace powered by AI and Machine Learning offering a real-time broker portal to connect shippers with qualified carriers
• Fr8Radar – A tracking solution providing shippers and carriers real-time locational data via Fr8app’s mobile solution or through integration with third-party GPS alternatives
• Fr8TMS – A transportation management system designed to help shippers manage their freight and all of the documents involved in shipping transactions, including invoices, customs documents, confirmation rates and proof of deliveries
• Fr8FMS – A fleet management system allowing transportation companies to better manage their fleets, reduce operational costs and provide better service to their customers
• Fr8Data – A data solution offering real-time dashboards and reports to shippers and carriers in an effort to increase visibility and control while supporting better business decisions
• Fr8Fleet – A platform that provides private fleet management, enabling large corporate shippers to purchase dedicated capacity secured by Fr8app in exchange for a fixed fee

Investment Considerations

• Fr8Tech aims to revolutionize cross-border shipping by providing shippers flexibility, visibility and simplicity.
• Through Fr8app, the company reduces human touch points and expedites load booking times.
• Fr8Tech seeks to lessen the carbon footprint of the logistics industry by minimizing empty miles for transportation firms and reducing overall paper consumption.
• The company’s established foothold in Mexico, the U.S.’s largest trade partner, is key to its current efforts to promote sustainable growth in the cross-border shipping industry.
• U.S.-Mexico cross-border annual freight spending is estimated at $385 billion.
• The company is led by a strong management team with decades of experience in transportation and technology.

- Recent Coverage -

July 26, 2022 8:30 AM

Freight Technologies (NASDAQ: FRGT), a technology company developing solutions to optimize and automate the supply chain process as well as providing a platform for B2B cross-border shipping in the NAFTA region, has been awarded a contract with Samsung Mexico in regard to its SDS business. According to the announcement, FRGT has already started to use its platform to assist with shipments from Mexico to the United States. Fr8App delivers cross-border capacity “during a difficult market when others have not been able to do so,” said a Samsung Mexico official, who noted that the company has more than 100 trucks going from Mexico to the United States every week. Fr8App provides ongoing administrative support of the logistics of those US-Mexico border shipments and eliminates the need for paper tracking, addressing a key piece of the company’s commitment to develop sustainable practices. Samsung Mexico SDS (formerly Samsung Data Systems) is a subsidiary of Samsung's Group. The company has been leading the digital transformation and innovation of the industry for more than three decades and has operations in some 40 countries. “Samsung, one of the world’s largest producers of electronic devices, selected Fr8App to ship from Mexico cross border to the United States, which we believe validates the Fr8App platform,” said Fr8Tech CEO Javier Selgas in the press release. “We believe this is just the beginning of many great things to come.”